methylprednisolone tablets recall
FDA recall D-0299-2026 · initiated Jan 15, 2026
Greenstone Llc recalled methylprednisolone tablets in Jan 2026 — an FDA Class II recall (D-0299-2026) because Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.
Labelling, packaging or a product mix-up
The wrong information — or the wrong medicine — ended up in the pack. A mix-up is a manufacturing failure that can still be dangerous to swallow.
This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.
Is your product affected? Check the lot number
A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.
Quantity recalled: 3456 cartons
Details
- Product
- methylprednisolone tablets, USP Dosepak, 4 mg, 1 Blister Card per Carton containing 21 Tablets, Rx only, Distributed by: Greenstone LLC, Peapack, NJ 07977. NDC 59762-4440-2
- Recalling company
- Greenstone Llc
- Classification
- Class II
- Status
- Ongoing
- Type
- Voluntary: Firm initiated
- Distribution
- Nationwide within the United States
- Initiated
- Jan 15, 2026
- FDA report date
- Feb 4, 2026
This recall is linked to a product we cover: Medrol →
Frequently asked
- Was methylprednisolone tablets recalled?
- Greenstone Llc recalled methylprednisolone tablets in Jan 2026 — an FDA Class II recall (D-0299-2026) because Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil. May cause temporary or medically reversible harm; low probability of serious harm.
- Why was methylprednisolone tablets recalled?
- Per the FDA enforcement record, the reason for recall D-0299-2026 was: Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.
- Is a recalled methylprednisolone tablets dangerous to take?
- An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
- Which lots of methylprednisolone tablets are affected?
- Distributed: Nationwide within the United States. The recall covers these lots — Lot # LG7675, Exp. Date Nov 2026. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0299-2026.